{"id":808943,"date":"2025-02-05T06:03:53","date_gmt":"2025-02-05T11:03:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/"},"modified":"2025-02-05T06:03:53","modified_gmt":"2025-02-05T11:03:53","slug":"theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/","title":{"rendered":"Theravance Biopharma to Participate in an Upcoming Investor Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n DUBLIN<\/span>
\n <\/span>, Feb. 5, 2025<\/span><\/span> \/PRNewswire\/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th<\/sup> Annual Healthcare Life Sciences Conference on Wednesday, February 12<\/span> at 12:00 pm EST<\/span> (9:00 am PST<\/span>\/5:00 pm GMT<\/span>).\u00a0<\/p>\n

\n

\n
\n \"Theravance
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Webcast of the event may be accessed by visiting Theravance.com<\/a>, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company’s website for 30 days.<\/p>\n

\n About Theravance Biopharma <\/b>\n <\/p>\n

Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference<\/i>\u00ae<\/sup> in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI\u00ae<\/sup> (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating\/driving shareholder value.<\/p>\n

For more information, please visit www.theravance.com<\/a>.<\/p>\n

THERAVANCE BIOPHARMA\u00ae<\/sup>, THERAVANCE\u00ae<\/sup> and the Cross\/Star logo are registered trademarks of the\u00a0Theravance Biopharma\u00a0group of companies (in the\u00a0U.S.\u00a0and certain other countries).<\/p>\n

YUPELRI\u00ae<\/sup>\u00a0is a registered trademark of\u00a0Mylan Specialty L.P., a\u00a0Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.<\/p>\n

Contact:
investor.relations@theravance.com<\/a>
650-808-4045<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302368408.html<\/a><\/p>\n

SOURCE Theravance Biopharma, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire DUBLIN , Feb. 5, 2025 \/PRNewswire\/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST\/5:00 pm GMT).\u00a0 Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company’s website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference\u00ae in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI\u00ae (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive … <\/p>\n

Continue reading “Theravance Biopharma to Participate in an Upcoming Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-808943","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTheravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Theravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DUBLIN , Feb. 5, 2025 \/PRNewswire\/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST\/5:00 pm GMT).\u00a0 Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company’s website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference\u00ae in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI\u00ae (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive … Continue reading "Theravance Biopharma to Participate in an Upcoming Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T11:03:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Theravance Biopharma to Participate in an Upcoming Investor Conference\",\"datePublished\":\"2025-02-05T11:03:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/\"},\"wordCount\":272,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/\",\"name\":\"Theravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"datePublished\":\"2025-02-05T11:03:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Theravance Biopharma to Participate in an Upcoming Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Theravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/","og_locale":"en_US","og_type":"article","og_title":"Theravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk","og_description":"PR Newswire DUBLIN , Feb. 5, 2025 \/PRNewswire\/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST\/5:00 pm GMT).\u00a0 Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company’s website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference\u00ae in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI\u00ae (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive … Continue reading \"Theravance Biopharma to Participate in an Upcoming Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-05T11:03:53+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Theravance Biopharma to Participate in an Upcoming Investor Conference","datePublished":"2025-02-05T11:03:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/"},"wordCount":272,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/","name":"Theravance Biopharma to Participate in an Upcoming Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","datePublished":"2025-02-05T11:03:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Theravance Biopharma to Participate in an Upcoming Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=808943"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/808943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=808943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=808943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=808943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}